Results 101 to 110 of about 59,140 (257)

Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2 [PDF]

open access: yes, 2015
Rationale: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodelling and cardiac hypertrophy.
Aronsen, Jan M.   +24 more
core   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

Endocrinologic Control of Men's Sexual Desire and Arousal/Erection [PDF]

open access: yes, 2016
Several hormones and neurotransmitters orchestrate men's sexual response, including the appetitive (sexual desire) and consummative (arousal and penile erection) phases.
Aversa, Antonio   +4 more
core   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz   +8 more
wiley   +1 more source

Regiodivergent C3 and C4 Amination of Quinolines via Radical and Ionic Pathways

open access: yesAngewandte Chemie, Volume 138, Issue 16, 13 April 2026.
A regiodivergent strategy converts a single N‐aminoquinolinium precursor into either C3‐ or C4‐aminated quinolines. Nucleophile‐induced dearomatization diverges into light‐driven N‐centered radical capture (C3) or base‐promoted SNAr (C4), enabling rapid assembly of aminoquinoline libraries and late‐stage diversification.
Ye‐Eun Kim   +3 more
wiley   +2 more sources

Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease

open access: yesNature Aging, 2021
Jiansong Fang   +10 more
semanticscholar   +1 more source

The Impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 Diabetes Mellitus: A Systematic Review. [PDF]

open access: yes, 2015
To determine the impact of poor glycaemic control on the prevalence of erectile dysfunction among men with type 2 Diabetics aged 27 to 85 years.The databases Embase classic+Embase, Global health, Ovid Medline and PsychINFO, were searched for relevant ...
Alsaad, S   +4 more
core   +1 more source

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye   +18 more
wiley   +1 more source

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial [PDF]

open access: yes, 2017
BACKGROUND: Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial hypertension (PAH). METHODS: Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking bosentan (62.5 ...
Dombi, Theresa   +4 more
core   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy